Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease

Jeffrey N Weiss, Steven Levy, Jeffrey N Weiss, Steven Levy

Abstract

Background: Stargardt Disease is the most common inherited macular degeneration, typically resulting in progressive central vision loss and legal blindness at an early age. We report regarding 34 eyes with Stargardt Disease treated in the Stem Cell Ophthalmology Treatment Study (SCOTS and SCOTS2). Methods: Autologous bone marrow was processed, separating the stem cell fraction which was provided Arms using retrobulbar, subtenons, intravitreal or subretinal and intravenous. The follow-up period was one year. Results: Of the 34 treated eyes, 21 (61.8%) improved, 8 (23.5%) remained stable, and 5 (14.7%) showed continued progression of their disease. Results were statistically significant with p = 0.0004. The average central vision improvement following treatment was 17.96% (95%CI, 16.39-19.53%) and ranged up to 80.5%. Of 17 patients treated, 13 (76.5%) showed visual acuity improvement in one or both eyes, 3 patients (17.6%) showed no net loss, and 1 worsened as a consequence of disease progression; 94.1% of patients had improved vision or remained stable. There were no adverse events. Conclusions: Patients with Stargardt Disease may potentially benefit from autologous bone marrow-derived stem cells (BMSC) as provided in SCOTS. Improvement or stabilization of vision was found to occur for the vast majority of reported patients and findings were highly statistically significant.

Keywords: ABCA4 mutation; BMSC; SGDT1; Stargardt Disease; bone marrow-derived stem cells; hereditary macular degeneration; hereditary maculopathy; juvenile macular degeneration; macular degeneration; stem cells.

Conflict of interest statement

The authors declare no conflict of interests.

References

    1. Tanna P., Strauss R.W., Gujinami K., Michaelides M. Stargardt Disease: Clinical features, molecular genetics, animal models and therapeutic options. Br. J. Ophthalmol. 2017;101:25–30. doi: 10.1136/bjophthalmol-2016-308823.
    1. Fujinami K., Lois N., Davidson A.E., Mackay D.S., Hogg C.R., Stone E.M., Tsunoda K., Tsubota K., Bunce C., Robson A.G., et al. A longitudinal study of Stargardt Disease: Clinical and electrophysiologic assessment, progression, and genotype correlations. Am. J. Ophthalmol. 2013;155:1075–1088. doi: 10.1016/j.ajo.2013.01.018.
    1. Fujinami K., Zernat J., Chana R.K., Wright G.A., Tsunoda K., Ozawa Y., Tsubota K., Robson A.G., Holder G.E., Allikmets R., et al. Clinical and molecular characteristics of childhood-onset Stargardt Disease. Ophthalmology. 2015;122:326–334. doi: 10.1016/j.ophtha.2014.08.012.
    1. [(accessed on 28 January 2021)]; Available online: .
    1. Kong X., West S.K., Strauss R.W., Munoz B., Cideciyan A.V., Michaelides M., Ho A., Ahmed M., Schönbach E.M., Cheetham J.K., et al. Progression of Visual Acuity and Fundus Autofluorescence in Recent-Onset Stargardt Disease: ProgStar Study Report #4. Ophthalmol. Retin. 2017;1:514–523.
    1. Weiss J.N., Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone marrow derived stem cells in the treatment of Age-Related Macular Degeneration. Medicines. 2020;7:16. doi: 10.3390/medicines7040016.
    1. Travis G.H., Golczak M., Moise A.R., Palczewski K. Diseases caused by defects in the visual cycle: Retinoids as potential therapeutic agents. Annu. Rev. Pharmacol. Toxicol. 2007;47:469–512. doi: 10.1146/annurev.pharmtox.47.120505.105225.
    1. Hussain R.M., Ciulla T.A., Berrocal A.M., Gregori N.Z., Flynn H.W., Jr., Lam B.L. Stargardt macular dystrophy and evolving therapies. Expert Opin. Biol. Ther. 2018;18:1049–1059. doi: 10.1080/14712598.2018.1513486.
    1. Schwartz S.D., Regillo C.D., Lam B.L., Eliott D., Rosenfeld P.J., Gregori N.Z., Hubschman J.-P., Davis J.L., Heilwell G., Spirn M., et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degenerations and Stargardt’s macular dystrophy:follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509–516. doi: 10.1016/S0140-6736(14)61376-3.
    1. Dalkara D., Goureau O., Marazova K., Sahel J.A. Let there be light: Gene and cell therapy for blindness. Hum. Gene Ther. 2016;27:134–147. doi: 10.1089/hum.2015.147.
    1. Audo I., Weleber R., Stout T., Lauer A.K., Pennesi M.E., Mohand-Said S., Barale P.-O., Buggage R., Wilson D.J., Sahel J.A. Early findings in a Phase I/IIa clinical program for Stargardt Disease. Investig. Ophthalmol. Vis. Sci. 2015;56:3819.
    1. Jimenez-Rolando B., Noval S., Rosa-Peres I., Diaz E.M., Del Pozo A., Ibañez C., Silla J.C., Montaño V.E.F., Martin-Arenas R., Vallespin E. Next generation sequencing in the diagnosis of Stargardt’s disease. Arch. Soc. Esp. Oftalmol. 2018;93:119–125. doi: 10.1016/j.oftal.2017.03.012.
    1. Trapani I. Dual AAV vectors for Stargardt Disease. Methods Mol. Biol. 2018;1715:153–175.
    1. Campa C., Gallenga C.E., Bolletta E., Perri P. The role of gene therapy in the treatment of retinal diseases: A review. Curr. Gene Ther. 2017;17:194–213. doi: 10.2174/1566523217666171116170040.
    1. Strauss R.W., Munoz B., Ho A., Jha A., Michaelides M., Cideciyan A.V., Audo I., Birch D.G., Hariri A.H., Nittala M.G., et al. Progression of Stargardt Disease as determined by fundus autofluorescence in the retrospective progression of Stargardt Disease study (ProgStar report no. 9) JAMA Ophthalmol. 2017;135:1232–1241. doi: 10.1001/jamaophthalmol.2017.4152.
    1. Waugh N., Loveman E., Colquitt J., Royle P. Treatments for dry age-related macular degeneration and Stargardt Disease: A systematic review. Health Technol. Assess. 2018;22:1–168. doi: 10.3310/hta22270.
    1. Weiss J.N., Benes S.C., Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow Derived Stem Cells in the Treatment of Lebers Hereditary Optic Neuropathy. Neural Regen. Res. 2016;11:1685–1694.
    1. Weiss J.N., Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone marrow derived stem cells in the treatment of Dominant Optic Atrophy. Stem Cell Investig. 2019;6:41. doi: 10.21037/sci.2019.11.01.
    1. Weiss J.N., Levy S. Stem Cell Ophthalmology Treatment Study: Bone marrow derived stem cells in the treatment of Retinitis Pigmentosa. Stem Cell Investig. 2018;5:18. doi: 10.21037/sci.2018.04.02.
    1. Weiss J.N., Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone marrow derived stem cells in the treatment of Usher syndrome. Stem Cell Investig. 2019;6:31. doi: 10.21037/sci.2019.08.07.
    1. Pesaresi M., Bonilla-Pons S.A., Simonte G., Sanges D., Di Vicino U., Cosma M.P. Endogenous Mobilization of Bone-Marrow Cells into the Murine Retina Induces Fusion-Mediated Reprogramming of Muller Glia Cells. EBioMedicine. 2018;30:38–51. doi: 10.1016/j.ebiom.2018.02.023.
    1. Molday R.S., Zhong M., Quazi F. The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degeneration. Biochim. Biophys. Acta. 2009;1791:573–583. doi: 10.1016/j.bbalip.2009.02.004.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren